Posted on November 23, 2010 by Albin Paul
Scott Stern, Associate Professor, Kellogg School of Management, speaks on the topic of, “New Drug Development: From Laboratory to Blockbuster to Generic,” at the Judicial Symposium on The Pharmaceutical Industry: Economics, Regulation, and Legal Issues, hosted by the Northwestern Law Judicial Education Program
Filed under: clinical research, Clinical Trial, drug development, drug discoverry | Tagged: Drug Development, drug discovey | Leave a Comment »
Posted on November 18, 2010 by Albin Paul
Canada’s Food and Drugs Act relies on drug companies to submit adverse reaction reports, which drug users submit if they suspect they are experiencing negative side effects. Drug users also can submit the reports directly to Health Canada, but it still leaves the government to rely on outside parties to report problems. In 2009, Health [...]
Filed under: clinical research, drug development, drug discoverry, Drug Safety, pharmacovigilance | Tagged: clinical research, Drug Safety, pharmacovigilance, post market surveillance | Leave a Comment »
Posted on November 17, 2010 by Albin Paul
Eli Lilly’s CIO Michael Heim says that the drug giant’s right to know where in the cloud its data resides, and to know the provider’s disaster recovery plans are chief issues that will drive the use of cloud computing in clinical data within drug discovery and development projects. An interview with Michael Heim is available [...]
Filed under: drug development, drug discoverry, Drug Discovery | Tagged: clinical data, cloud computing, Drug Development, drug discovery | Leave a Comment »
Posted on November 17, 2010 by Albin Paul
According to a new report from the Tufts Center for the Study of Drug Development at Tufts University 12 to 50 percent of the drugs companies are developing, depending on the company, involved a personalized medicine approach. The Tufts report is based on a survey of 25 companies, large and small, to which 16 companies [...]
Filed under: clinical research, Clinical Trial, drug development, drug discoverry, personalized medicine, Pharmacogenomics, Theranostics | Tagged: Drug Development, drug discovery, personalized medicine, theranostics | Leave a Comment »
Posted on November 29, 2009 by Albin Paul
The Coverage of the World Ecconomic Forum India Economic Summit is available at http://blog.livemint.com/wefindia/ I was more interested in the Collaborative Strategy for Drug Development read the interview with Suven Lifesciences a prefered partner to Eli Lilly and Co in Drug Discoverya dn Development in India. http://www.livemint.com/2009/11/10204140/India-Economic-Summit–Collab.html
Filed under: drug development, drug discoverry, Next Generation Drug Discovery | Tagged: collaborative drug development, collaborative drug discovery, health sciences global business unit, Oracle health sciences global business unit | Leave a Comment »
Posted on November 19, 2009 by Albin Paul
Did I really read the news correct or was I just plain drunk on a weekend while reading it. Turns out it is true. Just a week after the Novartis CEO has blasted the Indian IP laws, Novartis has announced plans to invest 1 Billion US Dollar in China for Drug Discovery and Developement. The [...]
Filed under: clinical research, Clinical Trial, drug development, drug discoverry, Drug Safety | Tagged: Glivec, health sciences global business unit, Novartis, Oracle health sciences global business unit | Leave a Comment »
Posted on November 18, 2009 by Albin Paul
The moment I learned about this new project started by MIT, I could think of only one thing, I want to be part of it. The Massachusetts Institute of Technology, have, started a pharmaceutical innovation program to help drug companies adapt some successful approaches now used in aeronautics, like lean management and information-sharing among rivals. [...]
Filed under: clinical research, digital DNA, drug development, drug discoverry, Next Generation Drug Development, Next Generation Drug Discovery, open access database | Tagged: health sciences global business unit, Oracle health sciences global business unit | 2 Comments »
Posted on January 30, 2008 by Albin Paul
Benjamin Franklin said “As we enjoy great advantages from the inventions of others we should be glad of an opportunity to serve others by any invention of ours; and this we should do freely and generously.” – Any one listening ! Leaders and veterans in Biotechnology and Health care research industry may not be welcoming [...]
Filed under: drug development, drug discoverry, Online Data sharing, open access database, open source, open source in biotechnoligy, web2.0 | 3 Comments »
Posted on July 19, 2007 by Albin Paul
Does eating a lotf of spicy curry eliminates the chances of geting cancer and diseases like Alzheimer’s thats a yummy proposition, I wish it was that easy, but apparently the Indian curry cuisines has the capacity to prevent the onset or delay the disease, but dont reach out for the qwik e mart yet. The [...]
Filed under: clinical diagnostics, DNA, drug development, drug discoverry, gene therapy, genetics, Genomics | 1 Comment »
Posted on July 18, 2007 by Albin Paul
Collaborative Drug Discovery Releases Next Generation Database for Both Private Collaborations and Public Open Access Collaborative Drug Discovery enables scientists to archive, mine, and collaborate to more effectively develop new drug candidates for commercial and humanitarian markets. The technology enables novel community-based research efforts that become more and more useful as additional participants contribute data. [...]
Filed under: drug development, drug discoverry, Online Data sharing, open access database, open source in biotechnoligy | Leave a Comment »
Posted on July 12, 2007 by Albin Paul
The Secret of how to prevent bacteria from developing drug resistance has been revealed in a new study.Drugs called bisphosphonates, widely prescribed for bone loss has been found to help in preventing an enzyme that helps in conjugation of bacteria, by help of which it derives drug resistance. Many highly-drug resistant bacteria rely on an [...]
Filed under: bacteria, DNA, DNA medicine, drug development, drug discoverry, drug resistance, genetic medicine, Genomics, microarray blog | Leave a Comment »
Posted on June 10, 2007 by Albin Paul
It takes upto to 15 years and multimillion dollar investments to patent and market one successful drug for pharmaceutical and biotech industry. Trying to make the sure that the scientists receive the best R&D support possible companies have looked at outsourcing and insourcing and everything else. And the new boy in the buzz world is [...]
Filed under: bioinformatics blog, drug development, drug discoverry, microarray blog, Online Data sharing, open access database, open source in biotechnoligy, outsourcing, science blog, six degrees of separation, web2.0 | 2 Comments »
Posted on April 19, 2007 by Albin Paul
Theranostics is the term used to describe the proposed process of diagnostic therapy for individual patients – to test them for possible reaction to taking a new medication and to tailor a treatment for them based on the test results or in plain english Personalized Medicine. Personalized medicine is the use of detailed information about [...]
Filed under: bioinformatics, bioinformatics blog, clinical diagnostics, clinical microarray, Clinical microarrays, DNA microarray, drug discoverry, epigenetics, gene expression, genetics, genotyping, microaray blog, microarray, microarray for clinical diagnostics, personalized medicine, Pharmacogenomics, science blog, Theranostics | 1 Comment »
Posted on March 27, 2007 by Albin Paul
REsearchers at columbia university medical centre newyork have developed a DNA-based computer that could lead to faster and more accurate diagnosis of west nile virus and bird flu. It is the first “medium -scale integrated molecular circuit” it is the most powerful comuting device of its type. Joanne Macdonald a virologist at columbia’s dapertment of [...]
Filed under: bioinformatics, bioinformatics blog, clinical diagnostics, digital DNA, DNA computer, drug discoverry, gene expression, genetics, microaray blog, microarray, Pharmacogenomics, science blog | 1 Comment »
Posted on March 21, 2007 by Albin Paul
A single test for more than 600 deadly viruses is being developed by a group of Defra-funded scientists, offering the possibility of spotting a disease outbreak in hours rather than days. The microarray, which is being led by the Central Science Laboratory near York, with £1.5m funding from Defra, will detect viruses that affect humans, [...]
Filed under: bioinformatics, bioinformatics blog, clinical diagnostics, clinical microarray, DNA, DNA microarray, drug discoverry, gene expression, genetics, genotyping, microaray blog, microarray, microarray for clinical diagnostics, microbe, Pharmacogenomics, science blog | Leave a Comment »
Posted on March 9, 2007 by Albin Paul
Junk DNA is not junk after all Recently, scientists at the University of Oxford have discovered that ‘junk’ genetic material can switch off cancer tumours, preventing them from growing. By using RNA to switch off a gene involved in controlling cell division, Oxford University scientists may have found a role for RNA in developing new [...]
Filed under: bacteria, biodefense, bioinformatics, bioinformatics blog, clinical diagnostics, clinical microarray, digital, DNA, DNA microarray, drug development, drug discoverry, epigenetics, gene expression, genetics, genotyping, microaray blog, microarray, microarray analysis, microarray for clinical diagnostics, Next Generation of DNA and RNA Microarrays, outsource, personalized medicine, Pharmacogenomics, RNA, RNA microarray | 1 Comment »
Posted on March 1, 2007 by Albin Paul
Two critical characteristics of breast cancer that are important to treatment can be identified by measuring gene expression in the tumor, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in Lancet Oncology online. Researchers developed and validated a new genomic microarray test that identifies whether a [...]
Filed under: Affymetrix, bioinformatics, bioinformatics blog, bioinformatics software, cancer, cancer microarray, clinical diagnostics, clinical microarray, Clinical microarrays, custom microarray, DNA, DNA microarray, drug development, drug discoverry, drug resistance, gene expression, genetics, genotyping, microaray blog, microarray, microarray analysis, microarray for clinical diagnostics, personalized medicine, Pharmacogenomics | 3 Comments »
Posted on March 1, 2007 by Albin Paul
Researchers from The Weizmann Institute of Science report the discovery of two new properties of the genetic code. Their work, which appears online in Genome Research, shows that the genetic code—used by organisms as diverse as reef coral, termites, and humans—is nearly optimal for encoding signals of any length in parallel to sequences that code [...]
Filed under: bacteria, biodefense, bioinformatics, bioinformatics blog, bioinformatics software, DNA, DNA microarray, drug development, drug discoverry, drug resistance, epigenetics, gene expression, genetics, genotyping, microaray blog, microarray | 4 Comments »
Posted on February 27, 2007 by Albin Paul
A research team said this week it had developed a technology for storing digital data in the DNA of bacteria, which unlike most living organisms can survive for millennia in the right conditions. Japanese researchers have successfully stored messages in the DNA of bacteria. The hardiness of the hay bacillus bacteria ensures the digital data [...]
Filed under: bacteria, bioinformatics, bioinformatics software, digital, digital DNA, digtial bacteria, DNA, DNA for cryptography, DNA microarray, drug development, drug discoverry, genetics, Japan, microbe, Pharmacogenomics, RNA, science blog, six degrees of separation | 4 Comments »
Posted on February 21, 2007 by Albin Paul
What makes you different from everyone else on the planet may have less to do with the spelling of your genetic code than with a scattering of chemical “tags” that, like censor’s marks, render some of your genes unreadable.The code itself, after all, is 99.9 percent identical in all of us, so these peripheral elements [...]
Filed under: bioinformatics, cancer, clinical diagnostics, clinical microarray, custom microarray, DNA microarray, drug discoverry, epigenetics, gene expression, genetics, genotyping, microarray, personalized medicine, Pharmacogenomics | Leave a Comment »